Ligumsky, M., Kaminski, N., Schatz, A.,…& Compton, D. et al. (1995). Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, that Binds to Cannabinoid Receptors. Biochemical Pharmacology, 50(1):83-90.
Mechoulam, R., Panikashvili, D. & Shohami, E. (2002). Cannabinoids and Brain injury: Therapeutic Implications. Trends in Molecular Medicine, 8(2):58-61.
More, S.V.& Choi, D.K. (2015). Promising Cannabinoid Based Therapies for Parkinson’s Disease: Motor Symptoms to Neuroprotection. Molecular Neurodegeneration, 10(17), 1-26.
Moriera, F.A. & Crippa, J.A. (2009). The Psychiatric Side-effects of Rimonabant. Revista Brasiliera Psiquiatria, 31(2), 145-153.
Munro, S., Thomas, K.L. & Abu-Sharr, M. (1993). Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature, 365, 61-65.
Najjar, S., Pearlman., Alper, K., Najjar, A. & Devinsky, O. (2013). Neuroinflammation and Psychiatric Illness. Journal of Neuroinflammation, 10(43), 1-24.
Pancher, P. & Hasko, G. (2008).
Endocannabinoids and Cannabinoid Receptors in Ischaemia-Reperfusion Injury and Preconditioning. British Journal of Pharmacology, 153(2), 252-262
Parker, Linda. (2017). Cannabinoids and the Brain. Cambridge, MA: The MIT Press.
Pertwee, R.G. (2008). Ligands That Target Cannabinoid Receptors in the Brain: From THC to Anandamide and Beyond. Addiction Biology, 13(2), 147-159.
Petrosino, S., Ligresti, A. & Di Marzo, V. (2009). Endocannabinoid Chemical Biology: A Tool for the Development of Novel Therapies. Current Opinion in Chemical Biology, 13(3), 309-320.
Pype, P., Teuwen, I., Mertens, F., Sercu, M. & De Sutter, A. (2017). Suboptimal Palliative Sedation in Primary Care: An Exploration. Acta Clinica Belgica, June 5, 1-8.
Ruchlemer, R., Amit-Kohn, M., Raveh, D., & Hanus, L. (2015). Inhaled Medicinal Cannabis and the Immunocompromised Patient. Supportive Care in Cancer, 23(3):819-22.
Russo E.B. (2001). Hemp for Headache: An In-depth Historical and Scientific Review of Cannabis in Migraine Treatment. Journal of Cannabis Therapeutics, 1, 21–92.
Russo, E.B. (2015). Synthetic and Natural Cannabinoids: The Cardiovascular Risk. The British Journal of Cardiology, Editorial, 22(1), 7-9.
Russo, E.B. (2016a). The Endocannabinoid System in Health and Disease. Presentation at The United In Compassion Medicinal Cannabis Symposium, June 14th & 15th, Sydney, Australia. Retrieved from: https://www.youtube.com/watch?v=1s-dDGTt20c&index=3&list=PL9Eh5xA-yu4ZUfSi-jQD-kWsMN3EOG5eb&t=23s
Russo, E.B. (2016b). Beyond Cannabis: Plants and the Endocannabinoid System. Trends in Pharmacological Sciences, 37(7), 594-605.
Russo, E.B & Guy, G.W. (2006). A Tale of Two Cannabinoids: The Therapeutic Rationale for Combining Tetrahydrocannabinol and Cannabidiol. Medical Hypotheses, 66(2), 234-46.
Santosh, V. & Sravya, P. (2017). Glioma, Glutamate (SLC7A11) And Seizures-A Commentary. Annals of Translational Medicine, 5(10), 214.
Scotter, E.L., Abood, M.E. & Glass, M. (2010). The Endocannabinoid System as a Target for the Treatment of Neurodegenerative Disease.
British Journal of Pharmacology, 160(3),
480-498.
Shi, S., & Klotz, U. (2011). Age-Related Changes in Pharmacokinetics. Current Drug Metabolism, 12(7), 601-10.
Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M. & Mechoulam, R. (2011). Endocannabinoids and Traumatic Brain Injury. British Journal of Pharmacology, 163(7), 1402-1410.
Singh G., Rees J.H. & Sander, J.W. (2007). Seizures and Epilepsy in Oncological Practice: Causes, Course, Mechanisms and Treatment. Journal of Neurology, Neurosurgery and Psychiatry, 78(4), 342–9.
Sizoo, E.M., Braam, L., Postma, T.J., Roeline, H., Pasman, W., Heimans…& Taphoorn, M.J.B. (2010). Symptoms and Problems in the End-of-life Phase of High Grade Glioma Patients. Neuro-Oncology, 12(11), 1162-1166.
Sugiura, T. & Waku, K. (2000). 2-Arachidonoylglycerol and the Cannabinoid Receptors. Chemistry and Physics of Lipids, 108(1-2), 89-106.
Sulak, D., Saneto, R. & Goldstein, B. (February 28, 2017). Medical Marijuana for Seizures. Published on projectcbd.org. Retrieved from: https://www.projectcbd.org/article/medical-marijuana-seizures-sulak-saneto-goldstein
Theisen, Eloise. (2017). Cannabis for Seniors: Reducing Pharmaceuticals and Improving Quality of Life. Green Flower Media (www.learngreenflower.com). Original date of 2017 lecture unavailable. Retrieved from: https://www.learngreenflower.com/courses/63/Cannabis-For-Seniors-Reducing-Pharmaceuticals-and-Improving-Quality-of-Life
Torres, A., Linker, W., Land, D., & Gaudino, R. (2017). Study of Pesticides in Clones: Research Summary. Published by Steep Hill Labs, Inc., September 22. Retrieved from: https://landing.steephill.com/cleanclones
Tradounsky, G. (2013). Seizures in Palliative Care. Canadian Family Physician, 59(9), 951-955.
The United States of America As Represented by the Department of Health and Human Services, Original Assignee. Medicinal Acidic Cannabinoids. US patent 7807711 B2, issued January 27, 2011. Retrieved from: https://www.google.ch/patents/US7807711
Waldman, M., Hochhauser, E., Fishbein, M., Aravot, D., Shainberg., A. & Sarne, Y. (2013). An Ultra-low Dose of Tetrahydrocannabinol Provides Cardioprotection. Biochemical Pharmacology, 85(11), 1626-33.
Wallace, M., Martin, B. & DeLorenzo, R.J. (2002). Evidence for a Physiological Role of Endocannabinoids in Modulation of Seizure Threshold and Severity. European Journal of Pharmacology, 452, 295-301.
World Health Organization Essential Medicines in Palliative Care, Executive Summary. (2013). Houston: International Association for Hospice and Palliative Care.
Zendulka, O., Dovrtelova, G., Noskova, K., Turjap, M., Sulcova, A., Hanus, L., & Jurica, J. (2016). Cannabinoids and Cytochrome P450 Interactions. Current Drug Metabolism, 17(3), 206-226.
REFERENCES-Difficult Road Of Dying